Rising Prevalence Of Cancer Is Fueling The Market Due To Increasing Demand For Personalized Immunotherapy Approaches Is Supporting Development Across The MSI-H And dMMR Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The MSI-H And dMMR Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The msi-h and dmmr market has experienced substantial growth in recent years. It is anticipated to expand from $7.57 billion in 2025 to $9.32 billion in 2026, showing a compound annual growth rate (CAGR) of 23.1%. This historical growth can be attributed to the discovery of msi-h and dmmr biomarkers, the early success of immune checkpoint inhibitors, a rise in colorectal and endometrial cancer incidence, the expansion of molecular diagnostics, and regulatory approvals for biomarker-based therapies.

The msi-h and dmmr market size is expected to undergo substantial growth over the next few years. It is forecast to expand to $21.13 billion by 2030, achieving a compound annual growth rate (CAGR) of 22.7%. This growth trajectory during the forecast period is primarily driven by factors such as the increasing adoption of precision oncology, the expanded use of genomic testing in cancer care, the broadening of immunotherapy indications, rising investment in biomarker research, and the accumulation of clinical evidence supporting tumor-agnostic approaches. Prominent trends anticipated in the forecast period include the increasing uptake of immunotherapy for msi-h and dmmr tumors, the growing application of companion diagnostics for patient stratification, a heightened focus on tumor-agnostic cancer treatments, the expansion of combination immunotherapy regimens, and increased awareness of biomarker-driven oncology.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

What Influential Factors Are Boosting The MSI-H And dMMR Market Demand?

The increasing incidence of cancer is anticipated to drive expansion in the MSI-H and dMMR market in the future. Cancer is defined as a collection of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells throughout the body. The growing occurrence of cancer largely stems from an aging global population, given that the likelihood of developing cancer rises considerably with advancing age due to the accumulated impact of genetic alterations and extended exposure to various risk factors over many years. In oncology, MSI-H and dMMR serve to pinpoint tumors exhibiting elevated mutation rates resulting from deficiencies in DNA repair pathways. These biological markers assist in directing immunotherapy choices, since these particular tumors show a greater propensity to react positively to immune checkpoint inhibitors; moreover, they offer valuable information regarding patient prognosis and the presence of possible genetic syndromes. As an illustration, in January 2024, data from the American Cancer Society, a US-based non-profit organization, indicated that in 2023, approximately 1,958,310 new cancer diagnoses and 609,820 cancer fatalities were projected for the United States. These figures are forecasted to climb in 2024, with around 2,001,140 new cancer diagnoses and 611,720 deaths expected, underscoring an ongoing upward trend in cancer occurrence and fatalities. Consequently, the increasing prevalence of cancer is a key factor propelling the expansion of the MSI-H and dMMR market.

Which Segment Groups Define The MSI-H And dMMR Market Landscape?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Trends Are Influencing The MSI-H And dMMR Market?

Leading companies within the MSI-H and dMMR market are prioritizing the development of innovative therapies, particularly combination approaches, to elevate treatment effectiveness and enhance patient prognosis. This type of therapy for MSI-H and dMMR cancers integrates two or more distinct treatment methods, frequently utilizing immunotherapy agents such as checkpoint inhibitors, or combining immunotherapy with other modalities like chemotherapy, targeted therapy, or radiation. The objective of this strategy is to boost treatment responsiveness, circumvent resistance mechanisms, and extend survival rates in patients whose tumors display high microsatellite instability or deficient mismatch repair. As a notable instance, in April 2025, the US-based pharmaceutical company Bristol-Myers Squibb Company secured approval from the United States Food and Drug Administration (FDA) for the combined use of nivolumab (Opdivo) and ipilimumab (Yervoy). This combination was approved as a first-line treatment for metastatic colorectal cancer (mCRC) characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, thereby advancing therapeutic possibilities for this challenging subtype of cancer. This FDA clearance signifies a crucial advancement in the treatment landscape for MSI-H and dMMR cancers, introducing a novel and potent therapeutic alternative that targets multiple biological pathways to improve patient survival and response rates, thereby addressing previously unmet medical requirements in this patient population.

Who Are The Firms Contributing To The MSI-H And dMMR Market Ecosystem?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Access The Complete MSI-H And dMMR Market Report:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Contributes The Most To The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access MSI-H And dMMR Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795